Navigation Links
Shire's Replenished Portfolio Drives Excellent Quarterly Performance
Date:4/29/2010

DUBLIN, April 29, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company, announces results for the three months to March 31, 2010.

    Financial Highlights

                                                      Q1 2010(1)

    Product sales                                $718 million     -5%

    Product sales from core products(2)          $626 million    +36%

    Total revenues                               $816 million       -

    Non GAAP operating income                    $265 million    -19%

    US GAAP operating income                     $218 million     -4%
    Non GAAP diluted earnings per ADS                   $1.01    -21%
    US GAAP diluted earnings per ADS                    $0.89    -23%

    (1) Percentages compare to equivalent 2009 period.
    (2) Core products represent Shire's products excluding ADDERALL XR.
    Angus Russell, Chief Executive Officer, commented:

"This was an excellent first quarter performance with our core product sales up 36% and cash generation increasing 19% to $278 million. Despite the impact of authorised generic ADDERALL XR, total reported revenues in the quarter were at 2009 levels, reflecting our success in replenishing our portfolio with products providing strong growth and robust intellectual property. Across the business we saw significant developments: VYVANSE now has approximately a 14% share of the US ADHD market, our two recently launched products VPRIV and INTUNIV are performing well and in the EU REPLAGAL is now the leading Fabry treatment, with an estimated 60% market share.

We are investing in our growing int
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Pepscan Signs Partnering Agreement With Immunovo for its Therapeutic Vaccine Portfolio
2. ClearTrial to Demonstrate How a Top 20 Sponsor Achieved -1 Percent Cost Variance Across Their $130M Clinical Portfolio at Major Industry Conference
3. EUCODIS Bioscience Receives EUR 2 Million Cash Injection to Enlarge Product Portfolio and Develop International Markets
4. New Industry Research Identifies "Operational Gap" in Clinical Trial Portfolio Management
5. Karolinska Development Expands its Life Science Portfolio With BioChromix Pharma
6. MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology
7. The Pittsburgh Life Sciences Greenhouse Invests $725K in Portfolio Companies
8. Octapharma Aims to Expand U.S. Immune Globulin Therapy Portfolio
9. EUCODIS Bioscience Launches Lipase Portfolio
10. PharmaVentures Corporate Advisory Appoints Nikki Watkins as Practice Head, Product & Portfolio Strategy
11. Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 2013 was a banner ... State Technologies®. They saw continued independent research led by ... were awarded a $1 million grant from the Susanne ... and Behavior” a peer reviewed journal, Amy Grant highlighted ...
(Date:1/15/2014)... AudioNotch is the internet's leading provider of Notched ... tinnitus. Patients listen to sound therapy that is tailor-made ... weeks to months, their tinnitus volume decreases. , AudioNotch has ... and Notched White Noise. Now, AudioNotch is pleased to announce ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 ... Almshouse Road, Warrington, Pa. , Details: The Hepatitis ... finding a cure for hepatitis B and improving the quality ... Crystal Ball on Friday, April 11 at Warrington Country Club ...
(Date:1/14/2014)... San Diego, CA (PRWEB) January 14, 2014 ... based on the products of cells grown under simulated ... an international license agreement with Suneva Medical, Inc. for ... media (CCM). , This agreement is an ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... ... therapy. Two years after endovascular treatment, 88 percent of women avoided amputation compared to ... ... are at risk of lower-leg amputation fare even better than men when they have minimally ...
... divas of the nanoworld. In possession of alluring properties, ... cousins. On the plus side, they can withstand ... Yoke Khin Yap, an associate professor of physics at ... in a barbecue at half of those temperatures," he ...
... , , , , , SAN ... ), a biopharmaceutical company focused on developing and commercializing novel ... Chief Executive Officer, is scheduled to present at the 28th ... 2009 at the Westin St. Francis Hotel in San Francisco, ...
Cached Biology Technology:Women More Likely Than Men to Avoid Amputation After Minimally Invasive Therapy for Blocked Leg Arteries 2Women More Likely Than Men to Avoid Amputation After Minimally Invasive Therapy for Blocked Leg Arteries 3Harnessing the divas of the nanoworld 2NeurogesX to Present at J.P. Morgan Health Care Conference 2NeurogesX to Present at J.P. Morgan Health Care Conference 3
(Date:7/9/2014)... can alleviate the symptoms of Alzheimer,s disease, ... and effectively scavenge amyloid beta peptide in ... reduced and eliminated Aβ deposition in an ... significantly improved behavioral and cognitive impairment. Dr. ... Hospital of China Medical University, China immunized ...
(Date:7/9/2014)... numerous inhabitants of the sea: tiny haptophytes of the ... naked eye, when they are in bloom in spring, ... visible on satellite images. "Together with other phytoplankton, ... the global photosynthesis output," states Prof. Dr. Georg Pohnert ... process the greenhouse gas carbon dioxide CO2 ...
(Date:7/8/2014)... future health of the world,s coral reefs and the ... the ability of one tiny symbiotic sea creature to ... algae it cooperates with. , In the first study ... discovered that coralstiny reef-forming animals that live symbiotically with ... heat stress, called "bleaching," when they keep large energy ...
Breaking Biology News(10 mins):Short circuit in the food web 2For corals adapting to climate change, it's survival of the fattest -- and most flexible 2For corals adapting to climate change, it's survival of the fattest -- and most flexible 3For corals adapting to climate change, it's survival of the fattest -- and most flexible 4
... of the Spanish Foundation for Biodiversity, the Charter Provincial Council ... R+D Centre will be studying the re-stocking of the three ... of May, June and July, respectively, in three streams of ... information needed to be able to manage the species and ...
... This release is available in German . ... Germany, the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is to ... by the appropriate Grants Committee in Bonn. The new institutions ... half years, during which time they will receive total funding ...
... the Walter and Eliza Hall Institute in Melbourne, Australia, ... the UK,s peak academy promoting excellence in science. ... to the Royal Society in 2011, including four Australians. ... process on the basis of excellence in science. ...
Cached Biology News:A study will enable the survival and growth of the 3 development phases of the European eel 2DFG establishes 18 new research training groups 2DFG establishes 18 new research training groups 3DFG establishes 18 new research training groups 4DFG establishes 18 new research training groups 5DFG establishes 18 new research training groups 6DFG establishes 18 new research training groups 7DFG establishes 18 new research training groups 8DFG establishes 18 new research training groups 9DFG establishes 18 new research training groups 10Top Australian malaria researcher elected Fellow of the Royal Society 2Top Australian malaria researcher elected Fellow of the Royal Society 3
Goat polyclonal to FBXO2 ( Abpromise for all tested applications). entrezGeneID: 26232 SwissProtID: Q9UK22...
Phospho-TAK1 (Thr184/187) (90C7) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
Mouse monoclonal to Factor V Heavy Chain Immunogen: Purified human Factor V. Specificity: This antibody reacts with the activation C peptide (mw ~150,000) in the heavy chain of thrombin-cleave...
Gamma delta T Lymphocytes Purified Anti-Porcine clone MAC320, Isotype Rat IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
Biology Products: